The National Myelodysplastic Syndromes (MDS) Study.

• Suspected (e.g., persistent unexplained cytopenia, circulating peripheral
blasts etc.) MDS or MDS/MPN overlap disorders and undergoing diagnostic
work-up with planned bone marrow assessments OR
• Diagnosed with de novo or therapy-related MDS within 6-months of
enrollment per the World Health Organization (WHO) criteria1 and undergoing
clinical evaluation and planned bone marrow assessments to confirm MDS or
to evaluate disease status
• Bone marrow aspirate expected to be performed within 1 week of registration,
and in all cases must be performed no later than 4 weeks after enrollment
• Age 18 or older
• No prior treatment for MDS at entry and through the time of the entry bone
marrow aspirate
• No treatment with hematopoietic growth factors in prior 6 months
• B12 level, serum folate, ferritin, and Thyroid-Stimulating Hormone (TSH) tests
performed in prior 6 months
• No diagnosis of a solid tumor or hematologic malignancy within two years
prior to enrollment except for in situ cancer of the skin (basal or squamous
cell), cervix, bladder, breast, or prostate
• No treatment with radiation therapy in the two years prior to registration
• No non-hormonal treatment for malignancy within the two years prior to
• No established hereditary bone marrow failure syndrome
• No known primary diagnosis of aplastic anemia, classical paroxysmal
nocturnal hemoglobinuria, amegakaryocytic thrombocytopenic purpura, or
large granular lymphocyte leukemia
• Not enrolled in the Connect® MDS/AML Disease Registry
Alison Conlin, M.D.
Laurie Delanty

The Pacific Cancer Research Consortium clinical trials are offered at multiple locations throughout Oregon, Washington, Alaska, California, and Idaho. To find a location near you, please contact the Patient Engagement Center at 844-552-2734.